The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

Treatment with RBL was effective against recurrent CDI among high-risk patients when administered at home or in clinical settings.

Body mass index (BMI) may not provide the most accurate screening for skeletal muscle deficits among youth with pediatric‐onset inflammatory bowel disease (IBD), according to a study in the Journal of ...

The US FDA says it plans to use artificial intelligence to help speed the approval of new drugs and medical devices.

Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

Waist-to-height ratio had a better predictive value than BMI in assessing liver fibrosis and steatosis outcomes across ages and racial groups.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

Federal health officials pulled back a key recommendation that pregnant women get the COVID-19 vaccine, causing sharp criticism from experts.

Growth hormone was not associated with a lower risk for the composite liver outcome among patients with adult-onset craniopharyngioma.

Janus kinase (JAK) inhibitors are not associated with an increased risk for gastrointestinal perforation (GIP) among patients with rheumatoid arthritis (RA), according to study results published in ...